SUNESIS PHARMACEUTICALS RECEIVES MILESTONE PAYMENT FROM BIOGEN IDEC

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics, has received a $500,000 milestone payment from Biogen Idec (Nasdaq: BIIB) relating to the discovery of novel Raf kinase inhibitors for the treatment of cancer.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-07-2005/0004229486&EDATE=)